Evidence map›Paper›PMID 39190256›Full record

Observational studyInternational journal of hematology2024

Treatment of relapsed acute lymphoblastic leukemia in children: an observational study of the Japan Children's Cancer Group.

Hiroaki Goto, Akiko Kada, Chitose Ogawa, Ritsuo Nishiuchi, Junko Yamanaka, Akihiro Iguchi, Masanori Nishi, Kimiyoshi Sakaguchi, Tadashi Kumamoto, Shinji Mochizuki and 4 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hiroaki GotoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 2-138-4 Mutsukawa Minami-Ku, Yokohama, Kanagawa, Japan. hgoto3949@gmail.com.ORCID http://orcid.org/0000-0001-6737-1509
Akiko KadaClinical Research Center, NHO Nagoya Medical Center, Aichi, Japan.
Chitose OgawaDepartment of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
Ritsuo NishiuchiDepartment of Pediatrics, Kochi Health Sciences Center, Kochi, Japan.
Junko YamanakaDepartment of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan.
Akihiro IguchiDivision of Hematology, National Center for Child Health and Development, Tokyo, Japan.
Masanori NishiDepartment of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan.
Kimiyoshi SakaguchiDepartment of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Tadashi KumamotoDepartment of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
Shinji MochizukiDepartment of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan.
Hideaki UekiDepartment of Pediatric Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Yoshiyuki KosakaDepartment of Hematology and Oncology, Center of Childhood Cancer, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
Akiko M SaitoClinical Research Center, NHO Nagoya Medical Center, Aichi, Japan.
Hidemi ToyodaDepartment of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Japan Children's Cancer Group Relapsed Acute Lymphoblastic Leukemia (ALL) Committee conducted a prospective observational study (ALL-R14) to explore promising reinduction therapy regimens for relapsed ALL to investigate in future trials. In Japan, clofarabine- and bortezomib-based regimens were of interest since they were newly introduced for ALL in the study period (2015-2018). Seventy-five pediatric patients were enrolled in total. The 2-year event-free/overall survival rates in patients with first (n = 59) or second (n = 11) relapse were 40.1% (95% confidence interval [CI]: 25.5-52.3%)/66.3% (95% CI 52.3-77.0%) and 34.1% (95% CI 9.1-61.6%)/62.3% (95% CI 27.7-84.0%), respectively. Clofarabine- or bortezomib-based regimens were used only in patients with high-risk disease. The first reinduction therapy used in the 41 patients with early or multiple relapsed B-cell precursor ALL was clofarabine in 7 patients and bortezomib in 9 patients. The odds ratio for reinduction failure risk with a clofarabine- or bortezomib-based regimen compared with other regimens was 9.0 (95% CI 0.9-86.4, P = 0.057) or 1.9 (95% CI 0.4-8.7, P = 0.42), respectively. Thus, clofarabine- or bortezomib-based regimens had no obvious advantage as reinduction therapy for relapsed ALL in children.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBortezomibClofarabinePrecursor Cell Lymphoblastic Leukemia-LymphomaRecurrenceAdolescentChildChild, PreschoolFemaleHumansInfantJapanMaleProspective StudiesSurvival RateBortezomibClofarabineAcute lymphoblastic leukemiaBortezomibChildrenClofarabineRelapse

Identifiers

PMID39190256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.